

3.2.3 Number of research projects per teacher funded by Govt. and non-Govt. agencies during the year

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
A multi-site pragmatic prospective observational study assessing outcome and safety of oral chloroquine / hydroxychloroquine prophylaxis for Indian medical professionals at risk of COVID-19	Dr. Sohan Solanki	TRAC	Govt.	Medical and Health Sciences	5/11/2020	0.5	1 Years	TMC
A phase II randomized study to evaluate the efficacy of short-course RR CVEP regimen against short course EPOCH-RR in adolescent and adult seropositive Diffuse large B cell lymphoma	Dr. Manju Sengar	TRAC and Unrestricted Educational grants from Non-Govt. companies AND DONORS	Non-Govt.	Medical and Health Sciences	8/17/2020	139.65	2 Years	TMC
A prospective, multicentre, post-marketing phase IV study to assess the safety and efficacy of Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC)	Dr. Vikas Ostwal	Eisai Non-Govt. causticals, India Pvt. Ltd. 6th Floor, A Wing, Marwah Center, Krishnaia! Marwah Marg, Andheri East, Mumbai 400072. Maharashtra, INDIA. Phon	Non-Govt.	Medical and Health Sciences	1/12/2021	37.50	2 Years 6 Months	TMC
BIRAC - Early Translation Accelerator (ETA)	Dr. Amit Kunwar (Co-Investigator)	BIRAC	Govt.	Chemical Sciences	2021	199.1	18 months	RRCAT
COVID-19 with Hematological Cancers Registry of India (CHCRI)	Dr. Lingeraj Nayak	Hematology Cancer Consortium (HCC)	Non-Govt.	Medical and Health Sciences	3/23/2021	1.08	1 Years 6 Months	TMC
Designing thin film heterostructure of quantum materials	Dr. Debakanta Samal	Science and Engineering Research Board	Govt.	Physical Sciences	2020-21	22.53	3 years	IOP
Development of a Multi-omics based Neoplasia Discovery Platform to generate Personalized Vaccines for Gliomas	Dr. Sridhar Epari	ICMR	Govt.	Medical and Health Sciences	10/28/2020	27.20	3 Years	TMC
Evaluation of the effect of foot bathing on peripheral neuropathy in patients receiving oxaliplatin containing chemotherapy for GI cancer at Tata Memorial Hospital	Mrs. Anita D Souza	IASCC	Non-Govt.	Medical and Health Sciences	2021	2.41	3 Years	TMC
Evaluation of the role of the immune cell profile in the persistence of minimal residual disease and dynamics of the relapse in childhood T-cell lymphoblastic leukemia: a prospective observational study.	Dr. Prashant Tembhere	ICMR	Govt.	Medical and Health Sciences	8/19/2020	46.56	3 Years	TMC
Exploring Radiative Neutrino Mass Models through Dark Matter and Collider Experiment	Dr. Kirtiman Ghosh	Science and Engineering Research Board	Govt.	Physical Sciences	2020-21	6.61	3 Years	(From IOP)

Compilation of data as received from Dean-Academic of the various Cis/Occ of HBN

Prof. P. D. Naik
 Dean, Homi Bhabha National Institute
 प्रमुख विज्ञान भवन, अणुशास्त्रीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Frontier & Futuristic Technology (FFT) Division	Aditi Sen De	Department of Science & Technology (DST)	Govt.	Physical Sciences	2019-20	39.02	03 years	HRI
Frontier & Futuristic Technology (FFT) Division	Arun Kumar Pati	Department of Science & Technology (DST)	Govt.	Physical Sciences	2019-20	59.02	03 years	HRI
Genomic Profiling of SARS-CoV-2 Infection in the city of Mumbai	Dr. Nikhil Patkar	TRAC	Govt.	Medical and Health Sciences	6/2/2020	36.5	2 Years	TMC
Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial	Dr. Jigeeshu Divatia	The George Institute for Global Health Plot No. 57, Second Floor, Corporation Bank Building Nagarjuna Circle, Punjagutta, Hyderabad - 500 082, Telanga	Non-Govt.	Medical and Health Sciences	10/5/2020	6	2 Years	TMC
Indian Pulmonary Embolism Registry (IndiPER)	Dr. Sohan Solanki	ETERNAL HOSPITAL JAIPUR	Non-Govt.	Medical and Health Sciences	9/3/2020	0.15	2 Years	TMC
INSPIRE Faculty Fellowship	Dr. Bishnu Prasad Biswal	DST-INSPIRE	Govt.	Chemical Sciences	2021	35.00	5 Years	(From NISER)
INSPIRE Faculty Fellowship	Dr. Dipak Samanta	DST-INSPIRE	Govt.	Chemical Sciences	2021	35	5 Years	(From NISER)
Investigating the role of methyl ammonium ordering in apto electronic properties of hybrid perovsites	Dr. Dinesh Topwal	Science and Engineering Research Board	Govt.	Physical Sciences	2020-21	8.41	3 Years	(From IOP)
Investigating the role of RUNX1 and ID proteins for targeting the Cancer Stem Cell Population in primary and relapsed Epithelial Ovarian Cancer	PI: Dr Pritha Ray. COI: Dr Bharat Rekhi	Lady Tata Memorial Trust	Non-Govt.	Medical and Health Sciences	2021	49.99	3 years	TMC
JC Bose Fellowship Award	Ashoke Sen	Science & Engineering Research Board (SERB)	Govt.	Physical Sciences	2017-18	10.25	05 years	HRI
JC Bose Fellowship Award	Arun Kumar Pati	Science & Engineering Research Board (SERB)	Govt.	Physical Sciences	2018-19	10.5	05 years	HRI
Matrics - Matrics Expert Committee	R Thangadurai	Science & Engineering Research Board (SERB)	Govt.	Mathematical Sciences	2020-21	2.2	03 years	(From IPR)
MHRD-SPARC	DR SANOLI GUN	MHRD, NEW DELHI	Govt.	Mathematical Sciences	2019	20.00	3 YEARS	IMSc
MHRD-SPARC	DR AMRITANSHU PRASAD	MHRD, NEW DELHI	Govt.	Mathematical Sciences	2019	17.00	3 YEARS	IMSc
Molecular genetic analysis of Leukoplakia to identify high risk lesion	Manoj Mahimkar/ Neha Mittal	Terry fox foundation	Non-Govt.	Medical and Health Sciences	2020	167.38		TMC

Compilation of data as received from Dean-Academic of the various CIs/OCC of HBNI.

1094
 Dr. P. D. Naik / Prof. P. D. Naik
 Dean, Homi Bhabha National Institute
 Anushaktinagar, Mumbai - 400 094
 School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Seroprevalence of COVID-19 in slum and non slum areas of Mumbai	Dr. Rajesh Dikshit	i-spirit	Non-Govt.	Medical and Health Sciences	7/7/2020	201.01	3 Months	TMC
Soft- Theorems, S-Matrix and Flat-Space holography	Dr. Shamik Banerjee	Science and Engineering Research Board	Govt.	Physical Sciences	2020-21	2.2	3 Years	(From IOP)
Stochastic thermodynamics of active particles and fields	Dr. Debashis Choudhuri	Science and Engineering Research Board	Govt.	Physical Sciences	2020-21	2.2	3 Years	(From IOP)
SwarnaJayanti Fellowship & research grant	Dr. S K Agarwalla	Ministry of Science & Technology	Govt.	Physical Sciences	2020-21	3	5 Years	(From IOP)
TMH IRIS: Proposal for participation of TMH ICU in the Indian Registry of Intensive care (IRIS)	Dr. Atul Kulkarni	Chennai Critical Care Consultants Group	Non-Govt.	Medical and Health Sciences	3/15/2021	2.61	1 Years	TMC
A Double Blind, Placebo- Controlled, Randomized Phase III Study of IPATASERTIB in combination with Paclitaxel As a treatment for patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple Negative Breast cancer or Hormone Receptor -Positive, HER2 -Negative Breast Cancer	Dr. Sudeep Gupta	F. Hoffmann-La Roche Ltd (hereafter referred to as Roche) globally and in India through its affiliate, Roche Products (India) Pvt. Ltd. (RPIPL)	Non-Govt.	Medical and Health Sciences	7/1/2019	327.74	5 Years	TMC
A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients with Her2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer who have received Prior Treatment with Trastuzumab and a Taxane	Dr. Sudeep Gupta	ROCHE PRODUCTS PVT LTD	Non-Govt.	Medical and Health Sciences	2/29/2016	84.68	6 Years	TMC
A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIa and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)	Dr. Vijay Patil	Novartis Healthcare Pvt. Ltd.	Non-Govt.	Medical and Health Sciences	4/30/2019	89.05	7 Years	TMC
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-Pd-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of The Head And Neck	Dr. Kumar Prabhash	Roche Products (India)	Non-Govt.	Medical and Health Sciences	5/7/2018	141.74	7 Years	TMC
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)	Dr. Vikas Ostwal	AstraZeneca Non-Govt. India Ltd.	Non-Govt.	Medical and Health Sciences	11/19/2019	57.70	4 Years	TMC
A phase IV study to investigate the safety and efficacy of regorafenib in Indian patients with metastatic colorectal cancer (mCRC)	Dr. Vikas Ostwal	Bayer AG, D-51368 Leverkusen, Germany	Non-Govt.	Medical and Health Sciences	7/9/2018	87.49	4 Years	TMC

Compilation of data as received from Dean-Academic of various cis/occ of NBNF.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, एच. बी. भाट्टी नॅशनल इंस्टीट्यूट
 प्रशिक्षण संस्थान, अणुशांतीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
National Post-Doctoral Fellowship in Physical Science	Dr. Sourya C	Science and Engineering Research Board	Govt.	Physical Sciences	2019-20	9.60	2 Years	(From IOP)
National Supercomputing Mission (NSM)	Sudip Chakraborty	National Supercomputing Mission (NSM)	Govt.	Engineering Sciences	2020-21	35.14	Not mentioned	(From IPR)
Observation or upfront cranial RT in oncogene driver mutated NSCLC with asymptomatic brain metastases. A phase III Randomized Controlled Trial	Dr. Anil Tibdewal	EM- NEUROONCOLOGY RESEARCH FUND	Non-Govt.	Medical and Health Sciences	7/23/2020	85.6	5 Years	TMC
PIK3CA Registry- A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer.	Dr. Sudeep Gupta	NOVARTIS HEALTHCARE PRIVATE LIMITED	Non-Govt.	Medical and Health Sciences	11/11/2020	9.76	2 Years	TMC
Project I - Early Detection of Common Cancers among Women in India	Dr. Rajendra Badwe	National Institute Of Health, USA	Non-Govt.	Medical and Health Sciences	1996	1061	26 Years	TMC
Protocol No. - ACE-ID-201 (D822FC00001) : A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19	Dr. Anant Ramaswamy	Astrazenca Non-Govt. India Ltd	Non-Govt.	Medical and Health Sciences	7/20/2020	74.55	6 Months	TMC
Protocol No. - D9106C00001 : A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)	Dr. C. S. Pramesh	Astra Zeneca AB	Non-Govt.	Medical and Health Sciences	1/8/2021	66.47	7 Years	TMC
QITPD-ICPS	Dr. C M CHANDRASEKHAR	DST NEWDELHI	Govt.	Physical Sciences	2019	31.98	5 YEARS	IMSc
QITPD-ICPS	Dr. SIBASISH GHOSH	DST NEWDELHI	Govt.	Physical Sciences	2019	37.12	5 YEARS	IMSc
Role of water pollution in development of esophageal cancer: a case-control stratified by high and low risk regions.	Dr. Rajesh Dikshit	Department of Health Research	Non-Govt.	Medical and Health Sciences	8/6/2020	65.8	2 Years	TMC
SERB MCOMS	DR. SUSHMITA GUPTA	SERB NEW DELHI	Govt.	Mathematical Sciences	2021	3.8	3 YEARS	(From IOP)
SERB novel pantronic phase in the functional quantum	Dr. Ajith C Balram	SERB NEW DELHI	Govt.	Mathematical Sciences	2020	28.6	2 YEARS	(From IOP)
SERB TOPOLOGY	PROF PRALAY CHATTERJEE	SERB NEW DELHI	Govt.	Mathematical Sciences	2021	2.2	3 YEARS	(From IOP)

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अनुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when Given in Combination with Paclitaxel in Patients Diagnosed with HER2 Positive Metastatic Breast Cancer.	Dr. Shalaka Joshi	ALKEM LABORATORIES LTD	Non-Govt.	Medical and Health Sciences	11/13/2017	57.36	4 Years 6 Months	TMC
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study)	Dr. Sudeep Gupta	AstraZeneca Non-Govt. India Limited	Non-Govt.	Medical and Health Sciences	10/14/2020	147.67	3 Years	TMC
A Prospective, Single arm, Multi-centre, Post-marketing Study (Phase IV) to evaluate safety and efficacy of Dr. Reddy's Trastuzumab (DRL_TZ) in Patients with HER2-Positive Cancer	Dr. Sudeep Gupta	Dr. Reddy's Laboratories	Non-Govt.	Medical and Health Sciences	2/24/2020	312.17	3 Years	TMC
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA).	Dr. Vikas Ostwal	AstraZeneca Non-Govt. India Ltd.	Non-Govt.	Medical and Health Sciences	5/18/2018	40.96	4 Years	TMC
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (MonarchE)	Dr. Seema Gulie	Eli Lilly and Company India Pvt. Ltd.	Non-Govt.	Medical and Health Sciences	4/9/2018	217.30	10 Years	TMC
A single arm, multicentric, open label, efficacy and safety study of Doceaqualip (Docetaxel Lipid Suspension for Injection of Intas Non-Govt. ceuticals Limited, India) based regimens in metastatic gastric adenocarcinoma patients	Dr. Vikas Ostwal	Intas Non-Govt. ceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India.	Non-Govt.	Medical and Health Sciences	2/27/2019	82.29	3 Years 10 Months	TMC
An observational, multicentre, Prospective study to evaluate concordance of detecting EGFR mutation by circulating tumour free DNA versus tissues biopsy in NSCLC (CONCORDANCE)	Dr. Kumar Prabhash	AstraZeneca Non-Govt. India Ltd	Non-Govt.	Medical and Health Sciences	10/26/2018	8.58	2 Years	TMC
An open label, phase I/II study of topical Apaziquone for the treatment of oral leukoplakia	Dr. Pankaj Chaturvedi	Spectrum Oncology Pvt Ltd	Non-Govt.	Medical and Health Sciences	6/30/2017	30.93	3 Years 9 Months	TMC
An Open-label, Single-arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® (Degarelix) in Androgen Deprivation Therapy in Indian Patients Diagnosed with Advanced Hormone-dependent Prostate Cancer.	Dr. Ganesh Bakshi	FERRING Non-Govt. CEUTICAL PVT LTD	Non-Govt.	Medical and Health Sciences	7/26/2017	11.09	3 Years 8 Months	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI

0094

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डी. एन. ए. प्रमुख, एम. एस. एम. संस्थान
 Dean, Homi Jhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Tumours	Dr. Gouri Pantvaidya	QBiotics Group Limited (QBiotics)	Non-Govt.	Medical and Health Sciences	12/9/2019	70.66	4 Years	TMC
Multicentre, randomised, double-blind, placebo controlled study of Atezolizumab (anti-PD-L1 antibody) in combination with paclitaxel compared with placebo in combination with paclitaxel for patients with previously untreated, inoperable locally advanced or metastatic Triple Negative Breast Cancer.	Dr. Sudeep Gupta	Roche Products (India) Pvt. Ltd	Non-Govt.	Medical and Health Sciences	4/18/2018	130.33	4 Years	TMC
Advancing Cancer-care through CANScrip™ Enabled Personalized Treatment (ACCEPT): A non-randomized, investigator initiated, observational trial to measure predictive power of CANScrip™ for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer	Dr. Shripad Banavali	Mitra Biotech Pvt. Ltd, Bangalore	Non-Govt.	Medical and Health Sciences	3/22/2018	100.00	4 Years	TMC
Processing of waste placental tissue from maternity wards into regenerative tissue grafts for non-healing wounds and other clinical applications	Dr. Ajay Puri	DST	Govt.	Medical and Health Sciences	2021	50	2 years	TMC
A Double Blinded Phase III Randomized Placebo Controlled Trial to Evaluate the Efficacy of Tranexamic Acid to Reduce Operative Blood Loss in Bone Tumor Patients	Dr. Ashish Gulia	BST DMG	Govt.	Medical and Health Sciences	4/21/2018	9.98	4 Years 6 Months	TMC
A clinical trial to test the number of circulating tumor cells (CTCs) captured by the OncoDiscover Liquid Biopsy Technology in peripheral blood samples of Head and Neck cancer patients.	Dr. Pankaj Chaturvedi	ACTORIUS INNOVATIONS AND RESEARCH PVT LTD.	Non-Govt.	Medical and Health Sciences	11/17/2017	10.16	4 Years 5 Months	TMC
A collaborative, multicentre, national trial for newly diagnosed patients with acute lymphoblastic leukaemia (ICICLE-2014)	Dr. Gaurav Narula	ICMR /NCG	Govt.	Medical and Health Sciences	6/2/2014	73.26	9 Years	TMC
A comparison of clinicopathological profile of non-B non-C hepatocellular cancer (HCC) and Hepatitis B or C related HCC	Dr. Prachi Patil	DAE	Govt.	Medical and Health Sciences	6/12/2017	.18	6 Years	TMC
A dosimetric and clinical study of DIBH in Mediastinal Lymphomas. An exploratory observational study	Dr. Jayant Goda	DST	Govt.	Medical and Health Sciences	6/11/2018	56.92	14 Years	TMC

Compilation of data as received from Dean-Academic of the various Cis/OCC of HBNT.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डॉ. होमी भाभा राष्ट्रीय संस्थान
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
A Feasibility and Safety Study of Single Application Multifractionated High Dose Rate Brachytherapy in Locally Advanced Cervical Cancer	Dr. Lavanya Naidu	DAE	Govt.	Medical and Health Sciences	3/7/2017	26.06	4 Years	TMC
A New Method for Cervical Cancer Screening in Low- and Middle-Income Countries (LMIC): Training and Technical Validation of Automated Visual Evaluation (AVE) in India	Dr. Rajesh Dikshit	Clinton Health Access Initiative (CHAI), USA	Non-Govt.	Medical and Health Sciences	10/23/2019	891.96	2 Years	TMC
A Phase 2 randomized controlled trial to evaluate the role of modified C.O.M.B.A.T maintenance regimen in children with high risk medulloblastoma	Dr. Girish Chinnaswamy	Terry Fox	Non-Govt.	Medical and Health Sciences	10/22/2018	56.42	4 Years	TMC
A Phase II Randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic non small cell lung cancer patients	Dr. Anil Tibdewal	DHR	Non-Govt.	Medical and Health Sciences	10/10/2019	56.36	6 Years	TMC
A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Govt.	Medical and Health Sciences	1/3/2020	451.02	5 Years	TMC
A phase II trial to study efficacy, toxicity and immunomodulatory effect of Carcitol-S in high grade serous epithelial ovarian cancer at first serological relapse	Dr. Amita Maheshwari	MINISTRY OF AYUSH,CCRAS,GOVT OF INDIA	Govt.	Medical and Health Sciences	4/24/2018	98.40	4 Years	TMC
A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Govt.	Medical and Health Sciences	7/10/2020	88.30	3 Years	TMC
A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer.	Dr. Sabita Jiwani	NOVARTIS HEALTHCARE	Non-Govt.	Medical and Health Sciences	7/23/2014	39.22	7 Years 2 Months	TMC
A Phase III randomized clinical trial to study the radiosensitizing effect of Nelfinavir in Advanced Carcinoma of Cervix. (NELCER Trial)	Dr. Supriya Chopra	VARIAN GRANT RESEARCH	Non-Govt.	Medical and Health Sciences	3/17/2017	225.96	8 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI

Dr. P. D. Naik
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer. (MONALEESA-7)	Dr. Jyoti Bajpai	Novartis Healthcare Private Limited	Non-Govt.	Medical and Health Sciences	12/10/2015	179.10	7 Years	TMC
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer (TEXT Trial)	Dr. Vani Parmar	IBCSG	Non-Govt.	Medical and Health Sciences	9/22/2005	30.36	16 Years	TMC
A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer (SOFT Trial)	Dr. Vani Parmar	INTERNATIONAL BREST CANCER STUDY GROUP	Non-Govt.	Medical and Health Sciences	8/29/2005	40.09	16 Years	TMC
A phase III, double blind, Placebo controlled, randomized trial assessing the effect of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumor. (Add Aspirin Study)	Dr. C. S. Pramesh	TATA TRUST	Non-Govt.	Medical and Health Sciences	9/2/2018	1560.33	10 Years	TMC
A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent.	Dr. Manju Sengar	Onconova Therapeutics, Inc.	Non-Govt.	Medical and Health Sciences	11/24/2018	10.52	3 Years	TMC
A phase-3 randomized control trial comparing hydroxyurea and L-asparaginase for cytoreduction in pediatric AML patients presenting with hyperleukocytosis	Dr. Shripad Banavali	SOHN FOUNDATION THROUGH GRAVIS	Non-Govt.	Medical and Health Sciences	9/27/2018	23.59	4 Years	TMC
A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Cervarix®)	Dr. Sharmila Pimpie	Serum Institute of India Pvt. Ltd. Hadapsar, Pune (Sponsor)	Non-Govt.	Medical and Health Sciences	6/28/2018	137.25	4 Years 9 Months	TMC
A pilot evaluation of prognostic molecular and serum biomarkers of disease recurrence after chemoradiation in patients with locally advanced cervical cancer from EMBRACE study group (BIO-EMBRACE-1)	Dr. Supriya Chopra	BIOEMBRACE RESEARCH GROUP	Non-Govt.	Medical and Health Sciences	2/5/2019	23.60	3 Years	TMC
A pilot study to determine the feasibility of detection of esophageal cancer by sponge cytology technique	Dr. Sabita Jiwani	Dr. Virginia R. Little, Boston University, Collamore 7, Suite7380	Non-Govt.	Medical and Health Sciences	5/11/2020	.08	2 Years 6 Months	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI

प्रो. पी. डी. नाईक / Prof. P. D. Naik
डीन, होमी भाभा राष्ट्रीय संस्थान

Dean, Homi Bhabha National Institute

एशिया विद्यालय भवन, अणुशास्त्रांग, मुंबई - 400 094

Training School Complex, Anushaktinagar, Mumbai - 40

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
A prospective evaluation of a point of care saliva-based detection test based on soluble CD44 (OncAlert) for the presence of disease in a previously untreated oral cavity and oropharynx squamous cell carcinoma.	Dr. Sudhir Vasudevan Nair	Tata Trusts, Vigilant Biosciences	Non-Govt.	Medical and Health Sciences	12/13/2018	17.06	4 Years	TMC
A prospective observational study to compare speech and swallowing outcomes in patients undergoing treatment for oral tongue cancers	Dr. Shiva Kumar Thiagarajan	ICON	Non-Govt.	Medical and Health Sciences	12/16/2019	10.00	3 Years	TMC
A prospective observational study to determine the risk of Hepatitis B viral reactivation in adolescent and adult acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) with Occult Hepatitis B infection (OHBI).	Dr. Hasmukh Jain	UNRESTRICTED EDUCATIONAL GRANT	Non-Govt.	Medical and Health Sciences	10/25/2016	2.51	8 Years	TMC
A prospective study to evaluate the feasibility of hippocampal sparing intensity modulated radiotherapy in preserving neurocognitive functions in adult patients with pituitary adenoma.	Dr. Jayant Goda	DAE	Govt.	Medical and Health Sciences	2/29/2016	4.45	6 Years	TMC
A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinoma	Dr. Sudeep Gupta	DAE	Govt.	Medical and Health Sciences	9/15/2014	1.92	6 Years	TMC
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study)	Dr. Sudeep Gupta	Astra Zeneca Non-Govt. India Limited	Non-Govt.	Medical and Health Sciences	10/14/2020	147.67	3 Years	TMC
A questionnaire survey to assess the quality of informed consent among clinical trial participants	Dr. Vikram Gots	INDOX Coordinating Centre, University of Oxford	Non-Govt.	Life Sciences	2/5/2009	3.09	1 Years	TMC
A randomized controlled trial to evaluate the safety of breast conserving surgery post neo-adjuvant therapy locally advanced breast cancer.	Dr. Nita Nair	DAE	Govt.	Medical and Health Sciences	6/12/2018	12.07	12 Years	TMC
A Randomized study comparing Weekly Paclitaxel plus Best Supportive Care to Best Supportive Care Alone in Patients with small cell lung cancer relapsed on two or more lines of chemotherapy (rel. small cell)	Dr. Kumar Prabhash	ICON	Non-Govt.	Medical and Health Sciences	4/11/2018	75.54	5 Years	TMC

Compilation of data as received from Dean-Academic of the various Cis/OCC of HBNI.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डॉ. लक्ष्मी भूषण राष्ट्रीय संस्थान
 Bhabha National Institute
 प्रशिक्षण संस्थान भवन, अनुशक्तीनगर, मुंबई
 Training School Complex, Anushaktinagar, Mumbai

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
A Randomized Study of the Safety and Efficacy of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer in Patients who Are not Candidates for Curative Surgery and/or Radiation and who Are Receiving Pemetrexed and Carboplatin	Dr. Amit Joshi	CLIANTHA RESEARCH LIMITED	Non-Govt.	Medical and Health Sciences	6/18/2018	36.76	2 Years 6 Months	TMC
A randomized study to evaluate the effectiveness of Gabapentin on Oral-Mucositis induced pain due to chemo-radio therapy in patients with head and neck cancers.	Dr. Nandini Menon	CADILA	Non-Govt.	Medical and Health Sciences	3/4/2020	21.22	3 Years	TMC
A randomized trial comparing intensity modulated external beam radiation alone vs intensity modulated radiation and brachytherapy for reduction in xerostomia in patients with early staged oropharyngeal cancers	Dr. Ashwini Budrukkar	DAE-CTC	Govt.	Medical and Health Sciences	6/6/2010	54.54	11 Years 8 Months 4 Days	TMC
A randomized trial of concurrent versus sequential Tamoxifen with radiotherapy to assess the extent of pulmonary fibrosis and disease related control and survival in breast cancer patients	Dr. Ashwini Budrukkar	ICMR	Non-Govt.	Medical and Health Sciences	5/7/2007	27.76	14 Years 9 Months 2 Days	TMC
A randomized trial to evaluate the efficacy and safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients	Dr. Kumar Prabhash	NATCO	Non-Govt.	Medical and Health Sciences	9/20/2010	15.44	12 Years	TMC
A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer.	Dr. Sushmita Rath	Tanvax Biologics Corp.	Non-Govt.	Medical and Health Sciences	8/13/2019	108.54	2 Years	TMC
A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib	Dr. Vanita Noronha	SANOFI HEALTHCARE INDIA PRIVATE LIMITED (SHIPL)	Non-Govt.	Medical and Health Sciences	7/14/2011	18.37	11 Years	TMC
A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes	Dr. Sarbani Ghosh Laskar	IAEA	Non-Govt.	Medical and Health Sciences	1/24/2017	10.53	6 Years	TMC
A study evaluating the efficacy of axillary reverse mapping in biopsy proven patients undergoing upfront surgery.	Dr. Vani Parmar	DAE	Govt.	Medical and Health Sciences	2/7/2020	2.90	2 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of H3MI.

प्रो. पी. वी. नाईक, Prof. P. V. Naik
 डॉ. अशुभ रानडे, Dr. Ashubh Ranade
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Advance Materials for Different Applications	Prof. Sudhakar Panda	DAE	Govt.	Chemical Sciences	2020	1.430.00	3 Years	NISER
Advanced Research Facility for Theoretical Physics	Prof. Pinaki Majumdar	DAE	Govt.	Physical Sciences	2020	61.11	3 Years	HRI
ALTO-EGF105708- A randomized, multi-center, open-label, phase III study of adjuvant Lapatinib, Trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer	Dr. Sudeep Gupta	NOVARTIS	Non-Govt.	Medical and Health Sciences	1/10/2008	77.45	15 Years	TMC
An Epidemiological Study To Evaluate The Prevalence of BRAF, PIK3CA& RAS Mutation In Indian Patients With Colorectal Cancer*	Dr. Vikas Ostwal	DR. REDDY'S LAB LTD	Non-Govt.	Medical and Health Sciences	10/29/2015	28.63	5 Years	TMC
An integrated network analysis to identify genomic alteration profiles of human perianapillary cancer	Dr. Shailesh Shrikhande	Department of Biotechnology, Government of India	Govt.	Medical and Health Sciences	7/30/2018	24.27	4 Years	TMC
AN OBSERVATIONAL STUDY TO DETERMINE THE ACCURACY OF OXYGEN RESERVE INDEX (ORI) TO PREDICT IMPENDING DESATURATION IN PATIENT'S UNDERGOING PROCEDURES UNDER APNOEA	Dr. Jeson Doctor	Smt KMD Medical Charitable Trust	Non-Govt.	Medical and Health Sciences	11/25/2020	1.30	2 Years	TMC
An observational study to determine the accuracy of oxygen reserve index (ORI) to predict impending desaturation in patients undergoing procedures under apnoea.	Dr. Jeson Doctor	Smt KMD Medical Charitable Trust	Non-Govt.	Medical and Health Sciences	11/25/2020	1.3	2 Years	TMC
An open label, prospective three-arm randomized, non-comparative study on efficacy and tolerability of orally disintegrating strip, oral tablets and intravenous administration of Vitamin B12, in post-gastrectomy Indian patients	Dr. Sujay Srinivas	EISAI Non-Govt. CEUTICALS, INTAS	Non-Govt.	Medical and Health Sciences	2/5/2020	38.34	6 Years	TMC
An Open label, Randomized, Investigator Initiated Multicentric, Phase III Study of Nimotuzumab in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Locally advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)	Dr. Kumar Prabhash	BIOCON	Non-Govt.	Medical and Health Sciences	5/9/2011	82.14	11 Years	TMC

Compilation of data as received from Dean-Academic of the various Cis/OCC of HBNI.

Dr. P. D. Naik
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400


Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
A study of lifelong vegetarianism and risk of colorectal cancer in India: an INDOX case control study	Dr. Shaesta Mehta	INDOX Cancer Research Network	Non-Govt.	Medical and Health Sciences	6/18/2012	.09	7 Years 5 Months 2 Days	TMC
A study of Low Dose Bevacizumab with conventional radiotherapy OR Ultra-Low Dose Radiotherapy alone in Diffuse Intrinsic Pontine Glioma. (LoBULaR-DIPG)	Dr. Rahul Krishnatry	Reliance Life Sciences Pvt Ltd + BRAIN TUMOR FUND	Non-Govt.	Medical and Health Sciences	12/5/2019	15.61	3 Years	TMC
A two arm randomized open label Phase II clinical trial to assess the efficacy of Gemcitabine-cisplatin or Capecitabine and Concurrent chemoradiation in Operated stage II & III GB cancer (GECCOR-GB)	Dr. Anant Ramaswamy	Zydus Non-Govt. ceuticals, Dr. Reddy's Laboratories Limited	Non-Govt.	Medical and Health Sciences	4/30/2019	15.72	3 Years	TMC
A two arm randomized open label prospective parallel design superiority Phase II multicentric clinical trial to evaluate the efficacy of a doublet second line chemotherapy versus monotherapy in advanced unresectable or metastatic gall bladder cancer progressing on first line chemotherapy (GB-SELECT)	Dr. Anant Ramaswamy	TERRY FOX	Non-Govt.	Medical and Health Sciences	10/3/2017	28.45	3 Years 6 Months	TMC
Absolute matrix order unit spaces: an order theoretic generalization of C^* -algebras	Dr. Anil Kumar Kam	SERB	Govt.	Mathematical Sciences	2021	6.6	3 Years	(From NISER)
Acceptability and validity of self sampling for high risk HPV detection among women in Maharashtra	Dr. Gauravi Mishra	PHFI THROUGH THE PH LEADER PRPGRAMME	Govt.	Medical and Health Sciences	3/2/2017	92.99	5 Years 2 Months	TMC
Acupuncture as a modality of treatment for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer-A Phase 3 Randomized Controlled Trial (ABC-CIPN)	Dr. Jyoti Bajpai	DAE	Govt.	Medical and Health Sciences	7/16/2018	12.12	4 Years	TMC
Adjuvant chemotherapy for operated ampullary AdenoCarcinomas based on Histology and Intensification : A two arm non - randomized open label prospective parallel adaptive design phase II clinical trial (APACHI)	Dr. Anant Ramaswamy	Educational Grant - Reliance Life Science	Non-Govt.	Medical and Health Sciences	4/16/2020	11.20	7 Years	TMC
Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST) - a prospective randomized control trial	Dr. Sudhir Vasudevan Nair	National Cancer Grid	Govt.	Medical and Health Sciences	11/16/2016	418.37	7 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC HBNI.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 अध्यक्ष, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 40
 Training School Complex, Anushaktinagar, Mumbai

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
BIONIC: Big Imaging Data Approach For Oncology in a Netherlands India Collaboration	Dr. Venkatesh Rangarajan	DEITY-Dept of Electronics Govt of India	Govt.	Medical and Health Sciences	10/5/2017	44.25	8 Years	TMC
Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India	Dr. Sudeep Gupta	BIOQUEST SOLUTIONS PVT LTD	Non-Govt.	Medical and Health Sciences	6/27/2014	2.87	6 Years 7 Months	TMC
BRNS	Dr. P.C. Mishra	BRNS	Govt.	DAE	2021	35.36	2021-2024	(From BARC)
Cancer Scan Project	Dr. Pratap K. Sahoo	Canostix GmbH, Germany	Non-Govt.	Physical Sciences	2021	22.2	3 Years	(From NISER)
CAPCYR07568/ METRO- ABC - A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses /Regimens with Metronomic Schedule in Patients with Metastatic Breast Cancer	Dr. Sudeep Gupta	SANOFI SYNTHELABO PVT	Non-Govt.	Medical and Health Sciences	3/23/2016	40.83	2 Years	TMC
Centre for Fundamental Studies	Prof. Sudhakar Panda	DAE	Govt.	Physical Sciences	2020	372.96	3 Years	NISER
Centre for inter Disciplinary Sciences	Prof. Sudhakar Panda	DAE	Govt.	Chemical Sciences	2020	3,524.00	3 Years	NISER
Characterization support involving XRD and HR-SEM-EDS	Dr. Nirav Jaminapera	Uniexcel Agencies and Services Private Limited.	Non-Govt.	Engineering Sciences	2020	3.73	12 months	(From IPR)
Clinical outcome of common cancers treated with radical intent at HBCH Sangrur- A Retrospective Analysis	Dr. Jai Prakash Agarwal	University of Pennsylvania Philadelphia, US	Non-Govt.	Medical and Health Sciences	10/17/2019	26.40	2 Years	TMC

Compilation of data as received from Dean-Academic of the various Cis/OCC of HBNI.


 Prof. P. D. Naik / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुयात्रीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
An Open Label, Single Arm, Multicentric, Phase IV study to evaluate the safety and efficacy of Bevacizumab of Intas Non-Govt ceuticals Limited in approved indications.	Dr. Sudeep Gupta	Intas ceuticals Ltd., 2nd Floor, Chinubhai Centre, Ashram Road, Ahmedabad - 380 009, Gujarat, India.	Non-Govt.	Medical and Health Sciences	6/21/2018	171.05	3 Years	TMC
An ultrasonographic analysis of gastric volume in patients posted for elective gastrointestinal surgeries	Dr. Rashma Ambulkar	DAE	Govt.	Medical and Health Sciences	10/9/2018	.90	2 Years	TMC
Androgen receptor expression in breast cancer: Clinical, pathological and prognostic significance	Dr. Asawan Patil	WCI	Govt.	Medical and Health Sciences	7/7/2010	4.10	7 Years 9 Months 19 Days	TMC
Asia CML Registry (ACR): Web based registry	Dr. Navin Khaitry	ASIAN Govt. RESERACH FUND	Non-Govt.	Medical and Health Sciences	6/27/2011	2.77	13 Years	TMC
Aspirin for Dukes C and high risk Dukes B colorectal cancers an international, multi-centre, double blind, randomized placebo controlled phase III trial	Dr. Shaesta Mehta	INDOX	Non-Govt.	Medical and Health Sciences	9/15/2011	3.00	11 Years 1 Months 4 Days	TMC
Assessing Trop 2 expression and its correlation with the anti-Trop2 immune status in ovarian cancer patients	Dr. Anita Maheshwari	ICMR NIRRH	Govt.	Medical and Health Sciences	9/24/2018	21.00	5 Years	TMC
ASSESSMENT OF PLATELET CROSSMATCH RESULTS BY SOLID PHASE RED CELL ADHERENCE ASSAY AMONG PEDIATRIC HEMATO-ONCOLOGY PATIENTS IN A TERTIARY CARE ONCOLOGY CENTRE	Dr. Priti Desai	Immucor India Pvt. Ltd.	Non-Govt.	Medical and Health Sciences	6/20/2019	1.20	11 Months	TMC
Basic Research in cellular & Modular	Prof. Sudhakar Panda	DAE	Govt.	Life Sciences	2020	1,711.00	3 Years	NISER
Biological effect of low and high dose radiation exposure on human peripheral blood mononuclear cells and tumour tissues of cancer patients. a prospective in-vivo study	Dr. Rajendra Badwe	DEPARTMENT OF ATOMIC ENERGY AND DBT	Govt.	Medical and Health Sciences	6/13/2017	398.18	5 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Development of a cohort study to identify and evaluate transitions in lifestyle and risk factors in a rural population with a low cancer disease risk at baseline.	Dr. Rajesh Dikshit	World Cancer Research Fund (WCRF), Center for Global Health Research (CGHR), International Agency for Research on cancer (IARC)	Non-Govt	Medical and Health Sciences	5/8/2008	3000.00	13 Years	TMC
DHANUSH : Docetaxel as radiosensitizer in Head And Neck cancer patients, Unsuitable for cisplatin based chemoradiation	Dr. Vijay Patil	ICON	Non-Govt	Medical and Health Sciences	5/4/2017	59.21	12 Years	TMC
Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children with Acute Lymphoblastic Leukemia: A Pilot Study	Dr. Maya Prasad	SOHN FOUNDATION	Non-Govt.	Medical and Health Sciences	4/12/2018	2.85	4 Years	TMC
Docetaxel or Cisplatin radiosensitizer in Head and Neck cancer patients for curative or adjuvant chemoradiation	Dr. Kumar Prabhash	Oncology Care Associates, ICON Trust	Non-Govt.	Medical and Health Sciences	9/10/2018	30.84	5 Years	TMC
DST - WOS A SCIENTIST SCHEME	DR ARPITA CHOUDHURY	DST NEWDELHI	Govt.	Physical Sciences	2019	10.00	3 YEARS	IMSc
DST IINSPIRE Faculty award	Dr. Chitrabhanu Chaudhuri	DST	Govt.	Mathematical Sciences	2021	86.27	5 Years	(From NISER)
DST under "Hydrogen and Fuel Cell" Scheme (3.2.2)	PI: Prof. Rohit Shrivastava, DEI, Agra, Co-PI: Dr. Mrinal R. Pai, ChD, BARC, Mumbai, Co-PI: Dr. A. M. Banerjee, ChD, BARC, Mumbai,	DST	Govt.	Chemical Sciences	2020	14.4	2020 -2023	(From BARC)
DST-SWARNAJAYANTHI FELLOWSHIP	DR SAKET SAURABH	DST NEWDELHI	Govt.	Physical Sciences	2019	.00		IMSc
Effect of COX-2 and EGFR suppression on markers of angiogenesis and proliferation in squamous cell carcinoma of oral cavity a prospective randomized study.	Dr. Sudhir Vasudevan Nair	SERB	Govt.	Medical and Health Sciences	7/8/2011	40.53	11 Years	TMC

Compilation of data as received from Dean-Academic of the Various Cis/OCC of HBNI.

[Signature]

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dept. Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अनुशक्तीनगर मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Clinicopathologic Features of Undifferentiated Round Cell Sarcomas of Bone and Soft Tissues	Dr. Bharat Rekhi	DAE	Govt.	Medical and Health Sciences	6/30/2017	8.08	4 Years 5 Months	TMC
Collaborative Action for Control of Cancer and Other Non-Communicable Diseases among Mumbai Police	Dr. Gauravi Mishra	Tata Trusts	Non-Govt.	Medical and Health Sciences	2/26/2019	740.21	3 Years	TMC
Comparative performance evaluation of Artificial Intelligence (AI) based visual inspection test (AI_VIA) with Primary Health Worker administered VIA (PHW_VIA), HPV DNA test and cervical cytology to detect cervical pre-cancer lesions.	Dr. Sharmila Pimple	Periwinkle Technologies Pvt. Ltd., Pune	Non-Govt.	Medical and Health Sciences	11/18/2019	6.68	3 Years	TMC
Comparing the disparate impacts of Oak and Chir pine tree species on their local hydrological and hydroclimatic regimes in the west-central Himalayas	Dr. Jaya Khanna Co-PI- Dr. Sumit Sen, IIT Roorkee Dr. Jagdish Krishnaswamy, ATREE	MHRD-STAR	Govt.	Physical Sciences	2020	97.08	3 Years	(From NISER)
COMPARISON OF TREATMENT ADHERENCE AND TOXICITIES OF HIV POSITIVE PATIENTS VS. HIV NEGATIVE CERVICAL CANCER PATIENTS IN INDIA	Dr. Lavanya Naidu	CRDF Global-ICMR	Non-Govt.	Medical and Health Sciences	10/30/2019	83.03	3 Years	TMC
CONcurrent versus SEquential Chemo-Endocrine therapy in ER positive and HER2 negative non-metastatic breast cancer (CONSEQUENCE)	Dr. Sheleka Joshi	CSR Fund from Gen. Insu. Co.	Non-Govt.	Medical and Health Sciences	8/1/2018	141.60	10 Years	TMC
DAE – RAJA RAMANNA FELLOWSHIP – PROF ROMESH K KAUL	PROF ROMESH K KAUL	DAE	Govt.	Physical Sciences	2018	1.82	3 YEARS	IMSc
Deep Learning neural network based radiogenomics in predicting clinicopathological outcomes in non-small cell lung cancer	Dr. Abhishek Mahajan	BIRAC-PREDIBLE HEALTH	Non-Govt.	Medical and Health Sciences	7/26/2018	6.74	4 Years	TMC
Development and Validation of an Electronic Surveillance System for Surgical Site Infections Developing During Hospital Stay and After Discharge: A Multi-Centric Study	Dr. Sheila Myatra	ICMR	Govt.	Medical and Health Sciences	12/5/2018	25.19	4 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 प्रिंसिपल डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, जगज्ज्वलनगर, मुंबई - 400 0
 Training School Complex, Anushaktinagar, Mumbai

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Evaluation of the diagnostic performance of HPV E6/E7 mRNA versus oncogenic HPV DNA as a secondary triage test for VIA positive women in cervical cancer screening program	Dr. Sharmila Pimple	DBT	Govt.	Medical and Health Sciences	2/11/2013	18.84	8 Years 1 Months	TMC
Evaluation of VEGF expression of tumor cells as a potential prognostic marker in Ewing's sarcoma	Dr. Jyoti Bajpai	Roche Products India Pvt. Ltd	Non-Govt.	Medical and Health Sciences	11/18/2016	62.37	7 Years	TMC
Experimental Condensed Matter Ultra Cold Atom	Prof. Sudhakar Panda	DAE	Govt.	Physical Sciences	2020	3,094.00	3 Years	NISER
Experimental High Energy Physics Programme	Prof. Sudhakar Panda	DAE	Govt.	Physical Sciences	2020	447.00	3 Years	NISER
Exploring the role of indigenously developed Chimeric Antigen Receptor (CAR) modified T- Cells in the therapy of relapsed/ refractory B-cell Acute Lymphoblastic Leukemia ineligible for Stem Cell Transplantation- Stage 2 & 3 of a Multi-stage Project	Dr. (Surg Cdr) Gaurav Narula	National BioNon-Govt. Mission	Govt.	Medical and Health Sciences	2021	.02	3 years	TMC
Exploring the role of TERT mutations in defining encapsulated papillary carcinoma of breast	Dr. Tanuja Shet	DAE	Govt.	Medical and Health Sciences	9/14/2017	8.50	2 Years	TMC
Feasibility and implications of thoracoscopic dissection of internal mammary nodes in central and inner quadrant breast cancer	Dr. Sabita Jiwnani	DAE	Govt.	Medical and Health Sciences	6/5/2015	28.44	7 Years	TMC
Genome-Wide Association Study to Identify Role of Genetic Susceptibility in Buccal Mucosa Cancer.	Dr. Sharayu Mhatre	DHR ICMR	Govt.	Medical and Health Sciences	9/25/2018	297.80	4 Years	TMC
Genomic Profiling in Thyroid Carcinoma	Dr. Anuradha Chougule	ICON	Non-Govt.	Medical and Health Sciences	8/17/2015	92.44	3 Years 6 Months	TMC
Genomics for Public Health in India (IndiGen) a Tongue Cancer Initiative	Dr. Amit Dutt	CSIR-Institute of Genomics and Integrative Biology (CSIR IGIB)	Govt.	Medical and Health Sciences	9/16/2019	907.80	2 Years 3 Months	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI

Prof. P. D. Naik / Prof. P. D. Naik
 Dean, Homi Bhabha National Institute
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Effect of intravenous iodinated contrast media on renal function in adults with estimated glomerular filtration rate <45 mL/min/1.73m ² . A randomized controlled non-inferiority trial	Dr. Akshay Baheti	DAE	Govt.	Medical and Health Sciences	12/4/2018	62.01	4 Years	TMC
Effectiveness and safety of 2 versus 3 doses of HPV Vaccine in preventing cervical cancer: An Indian multi-centre randomized trial	Dr. Sharmila Pimple	International Agency for Research on Cancer, World Health Organization, Lyon, France	Non-Govt.	Medical and Health Sciences	10/11/2008	252.25	18 Years	TMC
Effectiveness of a nurse- coordinated home care model in palliative care: a pilot study	Dr. Arunangshu Ghoshal	JEET ASSOCIATION FOR SUPPORT TO CANCER PATIENTS (JASCAP)	Non-Govt.	Medical and Health Sciences	1/9/2019	10.00	2 Years 6 Months	TMC
Efficacy of Bortezomib and Rituximab in newly diagnosed adolescent and adult CD20 positive Philadelphia (Ph) negative Precursor B-cell acute lymphoblastic leukemia: Phase II study	Dr. Manju Sengar	DAE	Govt.	Medical and Health Sciences	1/31/2017	65.44	5 Years	TMC
Esophagectomy Complications Platform and Quality Measures: What is the Contemporary Incidence of Complications at High Volume Esophagectomy Centers?	Dr. C. S. Pramesh	DAE	Govt.	Medical and Health Sciences	1/11/2018	23.57	10 Years	TMC
Establishment of audit for collating the data of lung cancer patients receiving systemic therapy with palliative intent in India.	Dr. Vanita Noronha	ICON	Non-Govt.	Medical and Health Sciences	10/8/2012	3.60	11 Years	TMC
Establishment of registry for Epidemiology and end result - analysis in lymphoma (REEA-L) and Establishment of lymphoma tumor tissue repository at the Tata Memorial Hospital (LTTR)	Dr. Navin Khattri	DR. REDDY'S LAB	Non-Govt.	Medical and Health Sciences	7/7/2010	55.00	13 Years 9 Months 19 Days	TMC
Evaluating the clinical utility of new immunophenotypic markers in the determination of minimal residual disease in childhood acute myeloid leukemia.	Dr. Prashant Tembhare	DAE	Govt.	Medical and Health Sciences	5/4/2018	4.03	4 Years	TMC
Evaluating The Role Of Genetic Susceptibility For Oropharynx Cancer In Indian Origin Population: a case-control study using the candidate gene approach	Dr. Sharayu Mhatre	ASCO (American Society of Cancer Oncology)	Non-Govt.	Medical and Health Sciences	3/27/2018	14.04	3 Years	TMC

Compilation of data as received from Dean - Academic of the various Cis/Occ of HBNI.


 प्रो. पी. डी. नाईक / Prof. P. D. Nair
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Inst
 प्रशिक्षण विद्यालय भवन, अणुसंशोधन संस्थान
 Training School Complex, Anushaktinagar

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Germ Cell tumor outcome and long term follow up study (GTOF)	Dr. Amit Joshi	DAE	Govt.	Medical and Health Sciences	9/5/2014	5.04	8 Years	TMC
Grid Oncology: Remaking Cancer Care in India	Dr. C. S. Pramesh	Wellcome Trust	Non-Govt.	Medical and Health Sciences	6/8/2020	30.36	3 Years	TMC
Health expenditure on breast cancer treatment in women: a study from public sector tertiary cancer centre (EXPERT)	Dr. Tabessum Wadasadawala	WCI-NAG foundation	Non-Govt.	Medical and Health Sciences	6/7/2019	10.00	4 Years	TMC
Hematological Cancers Consortium: HCC Leukemia Registry	Dr. Manju Sengar	HCC	Non-Govt.	Medical and Health Sciences	3/22/2019	116.84	10 Years	TMC
HEmodynamic Resuscitation and Monitoring in Early Sepsis (HERMES Study)	Dr. Sheila Myatra	ISCCM	Non-Govt.	Medical and Health Sciences	10/14/2019	1.00	2 Years 6 Months	TMC
High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure	Dr. Sheila Myatra	DAE	Govt.	Medical and Health Sciences	8/30/2018	3.28	4 Years	TMC
Histopathologic and Immunohistochemical Features of Solitary Fibrous Tumors of Soft Tissues	Dr. Bharat Rekhi	DAE	Govt.	Medical and Health Sciences	9/2/2016	6.72	4 Years 1 Months	TMC
Hypoxia Sensitive nanoparticle conjugates for targeted drug delivery in cancer	Dr. R. S. Ningthoujam (Principal Collaborator)	BRNS	Govt.	Chemical Sciences	2018	35	2018-2020	(From BARC)
Immunogenetics of Natural Killer cell receptors in HPV infected women with or without cervical cancer	Dr. Amita Maheshwari	BRNS/CENTRAL GOVERNMENT	Govt.	Medical and Health Sciences	8/8/2017	37.80	4 Years	TMC

Compilation of data as received from Dean-Academic of the various Cis/OCC of HBNI.

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Impact of Radiotherapy on Neuropsychiatric and Neurocognitive Burden in Patients with previously treated Pituitary Adenomas	Dr. Rahul Krishnatry	DAE	Govt.	Medical and Health Sciences	10/24/2019	17.39	3 Years	TMC
In Vitro and In Vivo Functions of Cell Surface Estrogen Receptors (csERs) in the Context of Prostate Cancer.	Dr. Ganesh Bakshi	DAE-BRNS	Govt.	Medical and Health Sciences	11/18/2019	34.89	3 Years	TMC
Incidence of post op emergence delirium in patients undergoing robotic transabdominal surgery with steep trendelenberg position-an observational study	Dr. Madhavi Shetmahajan	DAE	Govt.	Medical and Health Sciences	1/4/2019	.02	3 Years	TMC
INSA SRINIVASAN RAMANUJAN RESEARCH PROF R BALASUBRAMANIAN	PROF R BALASUBRAMANIAN	INSA NEWDELHI	Govt.	Mathematical Sciences	2018	12.00	4 YEARS	IMSc
Instrument automation for Optoelectronic Characterization of Tektronix Instruments	Dr. Satyaprasad Premswarup Senanayak	The Peridot Technologies	Non-Govt.	Physical Sciences	2021	1.44	1 Years	(From NISER)
Integration of Extended Immune Monitoring (ExImM) and clinical parameters for early prediction of disease trajectory/progression, treatment planning and prophylaxis to improve COVID-19 prognosis: Immunoprofiling Consortium by Indian Council of Medical Research (ICMR)	Dr. Prashant Tembhare	Indian Council of Medical Research (ICMR)	Govt.	Medical and Health Sciences	8/31/2020	97.71	2 Years	TMC
Integration of Extended Immune Monitoring (ExImM) and clinical parameters for early prediction of disease trajectory/progression, treatment planning and prophylaxis to improve COVID-19 prognosis: Immunoprofiling Consortium by Indian Council of Medical Research (ICMR)	Dr. Prashant Tembhare	Indian Council of Medical Research (ICMR)	Govt.	Medical and Health Sciences	8/31/2020	97.71	2 Years	TMC
Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: prospective observational study	Dr. Sarbani Ghosh Laskar	IMRT-IGRT/ Rapidarc Inc Ltd (Madison, WI, USA)	Non-Govt.	Medical and Health Sciences	2/1/2017	93.16	5 Years 6 Months	TMC
Interdisciplinary Cyber Physical Systems (ICPS) Division	Ujjwal Sen	Department of Science & Technology (DST)	Govt.	Physical Sciences	2019-20	81.58	03 years	HRI

Compilation of data as received from Dean-Academic of the various cis/occ of HBNI

प्रो. पी. डी. केशवराव (P. D. Keshavrao) Naik
डीन, अकादमिक संस्थान

Dean, Homi Bhabha National Institute

प्रशिक्षण विद्यालय भवन, अणुशक्तिनगर, मुंबई - 400 094

Training School Complex, Anushaktinagar, Mumbai - 400 0

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Introduction of a novel, cost effective, multigene panel for NSCLC patients - A pilot project	Dr. Rajiv Kumar	TMH, Central Government	Govt.	Medical and Health Sciences	6/19/2018	206.86	4 Years	TMC
Investigating the role of flow cytometric immunophenotyping in staging of pediatric solid round cell tumours	Dr. Prashant Tembhare	TMC	Govt.	Medical and Health Sciences	12/20/2016	9.95	4 Years 6 Months	TMC
Is extranodal Rosai Dorfman a different disease ?- Exploring BRAF, KRAS and MAP2K1 mutations in defining extranodal Rosai Dorfman disease.	Dr. Tanuja Shet	DAE	Govt.	Medical and Health Sciences	5/22/2018	10.84	2 Years	TMC
KINDLE- A multi-country, multi-centre, observational, retrospective study to reveal the patient characteristics, disease burden, treatment patterns and patient journey of stage III non-small-cell lung cancer patients	Dr. Kumar Prabhash	Astra Zeneca Non-Govt. India Ltd.	Non-Govt.	Medical and Health Sciences	7/25/2019	7.46	2 Years	TMC
Levy process on braided quantum groups and bosonization	Dr. Sutanu Roy	SERB	Govt.	Mathematical Sciences	2020	6.6	3 years	(From NISER)
INSPIRF Faculty Fellowship Program	Dr. Aparajita Mandal	Ministry of Science & Technology	Govt.	Physical Sciences	2020-21	22	1 Year	(From IOP)
INSPIRF Faculty Fellowship Program	Dr. Aparajita Mandal	MINISTRY OF SCIENCE & TECHNOLOGY	Govt.	DEPARTMENT OF SCIENCE & TECHNOLOGY	2020-21	22.00	one year	IOP
Low Cost Companion Diagnostic Test for Predicting Benefit of Adjuvant Chemotherapy in ER+ Breast Cancer	Dr. Vani Pamar	DBT	Govt.	Medical and Health Sciences	5/26/2016	142.89	6 Years	TMC
Mathematical Modeling and Subsequent Interactive Visualization to Reveal Underlying Patterns in Metastases from Head & Neck and Breast Cancers in India	Dr. Shalaka Joshi	Fulbright/Nehru Grant	Govt.	Medical and Health Sciences	7/12/2017	15.09	4 Years 1 Months	TMC

Compilation of data as received from Dean - Academic of the various Cis/OCC of HBNI

डॉ. प्र. डी. नाईक / Prof. P. D. Naik
 डीन, होमि ब्लोहा नेशनल इंस्टीट्यूट
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 0

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Max Plank Partner Group	Dr. Guneshwar Thangjam	Max Plank Partner Group	Non-Govt.	Physical Sciences	2020	84.68	5 Years	(From NISER)
Microbes Immunity & Research Biology	Prof. Sudhakar Panda	DAE	Govt.	Life Sciences	2020	1,655.00	3 Years	NISER
MK3475-593-03: A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) in India (Keynote-593)	Dr. Jyoti Bajpai	MSD ceuticals Pvt. Ltd	Non-Govt.	Medical and Health Sciences	6/30/2020	503.81	5 Years	TMC
MPI-IMSC PARTNER GROUP	PROF AREEJIT SAMAL	MAX PLANCK INSTITUTE	Non-Govt.	Life Sciences	2018	31.89	5 YEARS	IMSc
Multi-Centric Clinical Trials of Indigenous TKP 2.4: Implant and Pilot Production of TKP 2.4	Dr. Ashish Gulia	Non-ferrous Materials Technology Development Centre, Hyderabad	Non-Govt.	Medical and Health Sciences	2/18/2019	427.90	5 Years	TMC
National Post-Doctoral Fellowship	Dr. Avdesh Kumar under mentorship of Dr. Amaresh Kumar Jaiswal	SERB	Govt.	Physical Sciences	2021	21.31	2 Years	(From NISER)
Novel Organic Compounds for Biomedical	Prof. Sudhakar Panda	DAE	Govt.	Chemical Sciences	2020	1,452.00	3 Years	NISER
Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab compared with Chemotherapy in Patients with Treatment-Naive Advanced or Recurrent (Stage IIIB not amenable for multimodality treatment) or Metastatic(Stage IV) Non-Small Cell Lung Cancer who are deemed unsuitable for Platinum-Containing therapy	Dr. Kumar Prabhash	Roche Products (India) Pvt. Ltd	Non-Govt.	Medical and Health Sciences	11/23/2017	199.11	4 Years 4 Months	TMC
Parents' Experiences with Prognosis Communication about their Children with Advanced Cancer	Dr. Anuja Damani	ALLANASONS PVT LTD	Non-Govt.	Medical and Health Sciences	5/8/2019	10.00	3 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	CIs/OCC
Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer	Dr. Rahul Krishnatry	NRG Oncology	Non-Govt.	Medical and Health Sciences	10/10/2019	84.73	6 Years	TMC
Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer- CompARE trial	Dr. Devendra Chaukar	AstraZeneca/University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT	Non-Govt.	Medical and Health Sciences	9/14/2020	58.86	6 Years	TMC
Phase III randomized controlled trial of Image Guided Intensity Modulated Radiotherapy (IG-IMRT) and Conventional Radiotherapy for late toxicity reduction after postoperative radiotherapy in carcinoma cervix.	Dr. Supriya Chopra	DAE-CTC	Govt.	Medical and Health Sciences	10/21/2010	48.33	11 Years	TMC
Phase III Randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy	Dr. Supriya Chopra	NATIONAL RESEARCH GROUP (NRG)	Non-Govt.	Medical and Health Sciences	2/22/2019	92.16	9 Years	TMC
Phase III Study Evaluating Efficacy and Safety of low dose Gemcitabine compared to standard dose Gemcitabine with platinum in advanced non-small cell lung cancer	Dr. Kumar Prabhash	ICON	Non-Govt.	Medical and Health Sciences	11/2/2012	26.12	10 Years	TMC
Phase III trial of Observation versus Irradiation for a gross totally resected grade II Meningioma	Dr. Tejpal Gupta	NRG Oncology/RTOG	Non-Govt.	Medical and Health Sciences	4/11/2019	12.30	12 Years	TMC
Phase III, Assessor blinded, randomised controlled trial of the use of intraoperative neuromonitoring (IONM) in thyroid cancer surgery	Dr. Gouri Pantvaidya	TERRY FOX	Govt.	Medical and Health Sciences	4/12/2019	30.09	5 Years	TMC
Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study	Dr. Bhausheeb Bagal	Amgen Inc	Non-Govt.	Medical and Health Sciences	11/14/2019	122.98	4 Years 11 Months	TMC
PReCedeNT trial: Phase III randomised-controlled open-label trial of Lutetium - 177 Peptide Receptor Radionuclide Therapy (PRRT) Plus Chemotherapy Versus PRRT alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs)	Dr. Ameya Puranik	Terry Fox Foundation	Non-Govt.	Medical and Health Sciences	7/10/2019	24.00	8 Years	TMC

Compilation of data as received from Dean-Academic of the various CIs/OCC of HBNS

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डॉ. जे. एम. भागवत / Dr. J. M. Bhagwat
 Dear, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Pattern of care and survival studies Breast cancer	Dr. Rajesh Dikshit	NCRP, ICMR	Govt.	Medical and Health Sciences	7/31/2006	8.50	19 Years	TMC
Pattern of care and survival studies Head and Neck cancer	Dr. Rajesh Dikshit	NCRP, ICMR	Govt.	Medical and Health Sciences	7/31/2006	3.50	19 Years	TMC
Pattern of care and survival studies- cervix cancer	Dr. Amita Maheshwari	NCRP, ICMR	Govt.	Medical and Health Sciences	7/31/2006	8.50	19 Years	TMC
Performance of HPV DNA Test in presence of co-infection with common RTIs	Dr. Sharmila Pimple	DAE	Govt.	Medical and Health Sciences	6/14/2016	6.69	6 Years	TMC
Peripheral T-Cell Lymphoma: Impact of Immunophenotypic subsets, cytogenetic abnormalities, microenvironment and PI3K/NFKB on behavior	Dr. Tanuja Shet	DEPARTMENT OF BIOTECHNOLOGY	Govt.	Medical and Health Sciences	1/27/2017	135.98	5 Years	TMC
Perovskite based flexible thermoelectric power generators for portable power systems	Dr. Satyaprasad P. Senanayak	SERB	Govt.	Physical Sciences	2020	30.9	2 Years	(From NISER)
Phase 3 non inferiority randomised study between low dose immunotherapy and cytotoxic chemotherapy in 2nd line or beyond setting in relapsed-recurrent or metastatic solid tumors	Dr. Rajendra Badwe	Triokchand Papriwal Charitable Trust	Non-Govt.	Medical and Health Sciences	1/29/2020	331.29	5 Years	TMC
Phase I- Device Development: Development of portable transvaginal digital colposcope. Phase II- Development and Non-Inferiority Evaluation of a portable transvaginal digital colposcope with smartphone interface for single visit cervix cancer screening in low resource setting	Dr. Sharmila Pimple	Biotechnology Industry Research Assistance council (BIRAC)	Govt.	Medical and Health Sciences	5/3/2018	25.00	2 Years 6 Months	TMC
Phase IIb/III, Placebo-controlled, double-blind randomized clinical trial, using Curcumin and Metformin in patients with previous history of head and neck squamous cell carcinoma, in an attempt to lower the incidence of second primary tumor	Dr. Sudhir Vasudevan Nair	NATIONAL CANCER GRID	Non-Govt.	Medical and Health Sciences	9/28/2018	30.79	6 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.

प्रो. पी. डी. नाईक Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अनुसंधानावर, मुंबई - 400 094
 Training School Complex, Anushastan, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Tumor selective drug delivery using targeted micellar systems	Dr. Sanjay Tiwari, UKA Tarsadia Univ., Maliba Non-Govt. College, Gujarat (Principal Investigator) Gunjan Verma, Chemistry Division, BARC (Principal Collaborator)	UGC-DAE Consortium for Scientific Research	Govt.	Chemical Sciences	2020	4.77	April 2020 to March 2021 (Extendable to two more years after yearly review)	(From BARC)
Tumor Suppressors and Oncogenes: From Endometrial Cancer Cell Lines to Endometrial Cancer Tissues	Dr. Bharat Rekhi	NIRRH	Non-Govt.	Medical and Health Sciences	4/24/2019	5.00	2 Years 10 Months	TMC
Up gradation of pulsed DC power supply of Plasma Nitriding unit	Dr.-Ing.Suryakant Gupta	Indira Gandhi Centre for Atomic Research	Govt.	Engineering Sciences	2020	30.66	15 months	(From IPR)
Use of PET-CT with Gallium-68 labelled prostate Specific Membrane Antigen in the Diagnosis and Follow-up of patients with Prostate Cancer	Dr. Archi Agrawal	IAEA	Non-Govt.	Medical and Health Sciences	4/24/2018	16.22	4 Years	TMC
Utility of MRI in detecting peritoneal metastases in gastric cancer patients with negative CECT abdomen	Dr. Akshay Baheti	CIPLA	Non-Govt.	Medical and Health Sciences	1/22/2018	6.80	4 Years	TMC
Validation of the Beta Defensin Index (BDI) as a Biomarker for Oral Cancer - India	Dr. Deepa Nair	Case Western University, cleaveland	Non-Govt.	Medical and Health Sciences	10/30/2018	9.02	3 Years 6 Months	TMC
Validation of the Tata MD CHECK CRISPR SARS-CoV-2 test 1.0 for the diagnosis of COVID-19	Dr. Omshree Shetty	Tata Medical and Diagnostics Limited	Non-Govt.	Medical and Health Sciences	1/27/2021	2.93	3 Months	TMC
Validation of the TataMD CHECK CRISPR SARS-CoV-2 test 1.0 for the diagnosis of COVID-19	Dr. Omshree Shetty	Tata Medical and Diagnostics Limited	Non-Govt.	Medical and Health Sciences	1/27/2021	2.93	3 Months	TMC
Validation Study Of The HURRIA Score In Predicting Chemotherapy Toxicity Risk In Elderly Population Undergoing Chemotherapy For Breast, Gastrointestinal And Gynecological Cancers In Indian Setup	Dr. Vikas Ostwal	INTAS CEUTICAL PVT LTD	Non-Govt.	Medical and Health Sciences	8/9/2016	14.85	5 Years	TMC

Compilation of data as received from Dean Academic of the various CIS/OCC of HBNI.

0.094

Dr. P. D. Naik
 कुलपति भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Women Scientist Scheme A (WOS-A)	Aarti Girdhar	Department of Science & Technology (DST)	Govt.	Physical Sciences	2018-19	8.5	03 years	HR/
Chemistry of Materials for Energy, Environment and Health	Dr. A. K. Tyagi	DAE	Govt.	Chemical Sciences	2014	190.01	7 Years	BARC
Basic and Applied Research in Chemistry	Dr. C. N. Patra	DAE	Govt.	Chemical Sciences	2013	2285.07	7 Years	BARC
Technology Development and Applications of Isotopes	Dr. Y. K. Bhardwaj	DAE	Govt.	Chemical Sciences	2014	157.05	7 Years	BARC
Developing Novel Applications of Radiation Technology for Value Addition to Food & Agro Commodities	Dr. S. K. Ghosh	DAE	Govt.	Chemical Sciences	2014	6.41	7 Years	BARC
Development of New Alloys	Dr. Pranesh Sengupta	DAE	Govt.	Engineering Sciences	2014	110.46	7 Years	BARC
Experimental Studies for Ageing & Life Extension of Nuclear Components	Dr. V. Kain	DAE	Govt.	Engineering Sciences	2014	608.35	7 Years	BARC
Infrastructure and Component for launching of Advanced Heavy Water Reactor	Dr. N. K. Maheshwari	DAE	Govt.	Engineering Sciences	2014	1615.43	7 Years	BARC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.

(Signature)

प्र. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094


Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Synthesis, development and efficacy studies of functionalized Hollow Gold Nanoparticles for Glioblastoma	Dr. R. S. Ningthoujam (Principal Collaborator)	BRNS	Govt.	Chemical Sciences	2019	35	2019-2021	(From BARC)
The effect of resveratrol and copper on mortality in patients with hematological malignancies presenting with febrile neutropenia and sepsis or septic shock admitted to intensive care unit. A pilot study	Dr. Amol Kothekar	TRAC and ICMR	Govt.	Medical and Health Sciences	2/25/2020	13.94	2 Years	TMC
The molecular landscape of diffuse large B-cell lymphomas on the Indian sub-continent	Dr. Manju Sengar	DUKE GLOBAL HEALTH INSTITUTE /DBT	Non-Govt.	Medical and Health Sciences	5/31/2014	29.88	7 Years	TMC
Theoretical and computational investigations on the physical origins of rate-state friction- insights from a diverse set of normal stress step laboratory friction experiments	Dr. Pathikrit Bhattacharya	SERB	Govt.	Physical Sciences	2.02E+03	30.82	2 Years	(From NISER)
Theoretical High Energy & Condensed Matter	Prof. Sudhakar Panda	DAE	Govt.	Physical Sciences	2020	665.00	3 Years	NISER
Topological phase measurement in one-dimensional periodic and quasi-periodic photonic crystals	Dr. Ritwick Das and Dr. Pratap Kumar Sahoo	SERB	Govt.	Physical Sciences	2021	59.07	3 Years	(From NISER)
Total Marrow and Lymphoid Irradiation (TMLI) as conditioning regimen for peripheral stem cell transplant in high risk/relapsed /refractory leukemias.	Dr. Jayant Goda	extramural CSIR	Non-Govt.	Medical and Health Sciences	10/24/2019	61.31	5 Years	TMC
Transport coefficients near the critical point of strongly interacting matter	Dr. Guruprasad Prakash Kadam	DST-INSPIRE	Govt.	Physical Sciences	2021	22.48	5 Years	(From NISER)
Trastuzumab in HER2 positive Advanced Biliary tract cancers - single arm prospective phase II clinical trial (TAB trial)	Dr. Vikas Ostwal	Educational grant from Dr reddy' s limited	Non-Govt.	Medical and Health Sciences	10/28/2019	453.82	5 Years	TMC

Compilation of data as received from Dean Academic of the various Cis/OCC of HBNI

Dr. P. D. Naik
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094


Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
SERB W ALGEBRAS	PROF VISWANATH	SERB NEWDELHI	Govt.	Mathematical Sciences	2020	2.00	3 YEARS	IMSc
SERB-TARE DR SUNITHA V	PROF AREEJIT SAMAL	SERB NEWDELHI	Govt.	Life Sciences	2019	1.85	3 YEARS	IMSc
Special & Thematic Events in Mathematics	Prof. Pinaki Majumdar	DAE	Govt.	Mathematical Sciences	2020	2.20	3 Years	HRI
Structure of Hermitian modular forms modulo p and mod p kernel of theta function	Dr. Jaban Meher	SERB	Govt.	Mathematical Sciences	2020	30.42	3 Years	(From NISER)
Studies on lanthanides, actinides (U and Th) and toxic elements using nano-particle based solid adsorbents and neutron activation analysis	Dr. R. S. Ningthoujam (Principal Collaborator)	BRNS	Govt.	Chemical Sciences	2019	8	2019-2021	(From BARC)
Study of hormonal receptors in low grade endometrial stromal sarcoma and correlation with clinical parameters	Dr. Santosh Menon	Surbhi Nag Foundation	Non-Govt.	Medical and Health Sciences	8/27/2018	6.00	4 Years	TMC
Synthesis and characterization of boron nitride nanostructures	Dr. Balasubramanian C.	Vikram Sarabhai Space Center, ISRO	Govt.	Physical Sciences	2020	0	24 months	(From IPR)
Synthesis and characterization of novel photosensitizer textile dyes with photo-inactivation ability of viruses and other microbes: An expeditious approach to make self-cleaning and self-sterilizing fabric	Dr. Nabanita Sedhukhan, ICT Mumbai	BRNS	Govt.	DAE	2021	31.09	30-6-2021 to 29-6-2023 (3 years)	(From BARC)
Synthesis of Functional DNA Comprising Aminotriphyl 2' - deoxyuridine Analogues For Cross-linking with Peptides	Dr. Nagendra Kr. Sharma	SERB	Govt.	Chemical Sciences	2020	47.45	3 Years	(From NISER)

Compilation of data as received from Dean-Academic of the various Cis/OCC of HBNI.


 प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डी.डी. नाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 40


Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Rejuvenation of dying springs in Tokoli Gad Catchment of Tehri Garhwal District using Geo-Chemical & Geo-Physical techniques	Dr. Jaya Khanna	NMCG	Govt.	Physical Sciences	2020	6.5	3 Years	(From NISER)
Research in Basic Sciences	Prof. Sudhakar Panda	DAE	Govt.	Physical Sciences	2020	803.00	3 Years	NISER
Response Evaluation of Sclerotherapy for Vascular Malformations	Dr. Kunal Gala, Dr. Ashish Gulia, Dr. Ajay Puri	DST	Govt.	Medical and Health Sciences	2021	50	2 years	(From BARC)
Response-Adapted Management of Childhood Classical Hodgkin Lymphoma (cHL) and Early Response Assessment by Positron Emission and Computerized Tomography (PET-CT) to allow Omission of Radiotherapy in Indian Children Treated with a Standard of Care Intensified Chemotherapy Regimen	Dr. Badira Parambil	TRAC	Non-Govt.	Medical and Health Sciences	8/5/2020	46.02	8 Years	TMC
Response-Adapted Management of Childhood Classical Hodgkin Lymphoma (cHL) and Early Response Assessment by Positron Emission and Computerized Tomography (PET-CT) to allow Omission of Radiotherapy in Indian Children Treated with a Standard of Care Intensified Chemotherapy Regimen	Dr. Badira Parambil	TRAC	Non-Govt.	Medical and Health Sciences	8/5/2020	46.02	8 Years	TMC
Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence	Dr. Sudeep Gupta	OncoStem Diagnostics, Bangalore	Non-Govt.	Medical and Health Sciences	9/8/2014	14.66	7 Years 9 Days	TMC
Reverse swing-M : Repurposing of Mebendazole in recurrent glioblastoma	Dr. Vijay Patil	Brain Tumor Foundation, ICON CRSF, ICMR	Non-Govt.	Medical and Health Sciences	12/6/2017	47.98	5 Years	TMC
Role of HPV in etiology and progression of Head and Neck cancer	Dr. Rajesh Dixhit	ICMR	Govt.	Medical and Health Sciences	11/14/2013	49.29	6 Years 8 Months	TMC
Role of IL-9 and Th9 cells in T cell lymphoma with cutaneous involvement	Dr. Hasrnuh Jain	ICMR+ IIT-BOMBAY	Govt.	Medical and Health Sciences	3/8/2017	3.02	5 Years 6 Months	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNT.


 डॉ. पी. डी. नाईक / Prof. P. D. Naik,
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रनगर, मुंबई - 400 094
 Training School


Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Role of toll-like receptors and TLR agonists in modulating response to chemotherapy in TNBC patients	Dr. Shalaka Joshi	Funding received from Department of Biotechnology, BioCare call for proposal in 2018	Non-Govt.	Medical and Health Sciences	1/20/2020	41.13	3 Years 3 Months	TMC
Safety Study of Nivolumab for Selected Advanced Malignancies in India	Dr. Kumar Prabhash	Bristol-Myers Squibb Research and Development	Non-Govt.	Medical and Health Sciences	9/19/2017	107.82	3 Years	TMC
Salivary DNA as a diagnostic tool in Oral Cavity Squamous Cell Carcinoma (Salivary DNA Study)	Dr. Sudhir Vasudevan Nair	University of Chicago Trust in India, Bangalore	Non-Govt.	Medical and Health Sciences	3/29/2019	11.10	2 Years 6 Months	TMC
Scalp Cooling for the prevention of chemotherapy induced alopecia in breast cancer from a tertiary care cancer center in India	Dr. Jyoti Bajpai	Access Devices	Non-Govt.	Medical and Health Sciences	8/9/2016	5.77	8 Years	TMC
SERB – Explicit formulas for a class of general L functions Dr K Srinivas	PROF K SRINIVAS	SERB NEWDELHI	Govt.	Mathematical Sciences	2018	1.00	3 YEARS	IMSc
SERB – RAMANUJAN FELLOWSHIP – DR AREEJIT SAMAL	PROF AREEJIT SAMAL	SERB NEWDELHI	Govt.	Life Sciences	2015	4.00	4 YEARS	IMSc
SERB – RAMANUJAN FELLOWSHIP – DR C M CHANDRASHEKAR	PROF CHANDRASEKHAR	SERB NEWDELHI	Govt.	Physical Sciences	2015	.00	4 YEARS	IMSc
SERB AE COEFFICIENTS M FORMS	DR SANOLI GUN	SERB NEWDELHI	Govt.	Mathematical Sciences	2018	1.70	3 YEARS	IMSc
SERB W Algebra	Prof. Viswanath	SERB NEW DELHI	Govt.	Mathematical Sciences	2020	2	3 YEARS	(From IOP)

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.


 प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, आनुशक्तिनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 40

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (If applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Protocol No. - NIS/2018/19 : An open label, single arm, multicentric, observational study to evaluate safety and effectiveness of Akynzeo®, an oral fixed dose combination of netupitant and palonosetron in the management of CINV, in the real world settings of India	Dr. Sudeep Gupta	Glenmark Non-Govt.ceuticals Ltd.	Non-Govt.	Medical and Health Sciences	6/15/2020	10.41	2 Years	TMC
Protocol No. - TX05-03E : A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03	Dr. Sushmita Rath	Tanvex Biologics Corp.	Non-Govt.	Medical and Health Sciences	10/9/2020	116.24	2 Years	TMC
Protocol No. - TX05-03E : A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-	Dr. Sushmita Rath	Tanvex Biologics Corp.	Non-Govt.	Medical and Health Sciences	10/9/2020	116.24	2 Years	TMC
Protocol No. CABAZL06500- A phase II controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel in recurrent head and neck cancer in India	Dr. Kumar Prabhash	SANOFI	Non-Govt.	Medical and Health Sciences	1/29/2015	71.75	7 Years	TMC
Protocol no. CR201-18 A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- Controlled, Two Part, Phase III, Global Study to Evaluate the Non-Govt.cokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison with Herceptin®-EU in Patients with HER2-Positive Early Breast Cancer (EBC) and HER2-Positive Metastatic Breast Cancer (MBC)	Dr. Sushmita Rath	CuraTeQ Biologics GmbH c/o Moore Stephens Luzern AG, Obergrundstrasse 61, 6003 Luzern.	Non-Govt.	Medical and Health Sciences	1/27/2021	514.88	4 Years	TMC
Protocol no. CR201-18 A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- Controlled, Two Part, Phase III, Global Study to Evaluate the Non-Govt.cokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison with Herceptin®-EU in Patients with HER2-Positive Early Breast Cancer (EBC) and HER2-Positive Metastatic Breast Cancer (MBC)	Dr. Sushmita Rath	CuraTeQ Biologics GmbH c/o Moore Stephens Luzern AG, Obergrundstrasse 61, 6003 Luzern.	Non-Govt.	Medical and Health Sciences	1/27/2021	514.88	4 Years	TMC
Protocol No. EMR 062202 559- A prospective, open label, multicentric data collection registry in order to describe treatment choices in management of metastatic colorectal cancer (mCRC) patients with unresectable hepatic and / or extra hepatic disease, across treatment lines (Asian Metastatic Colorectal Cancer Registry)	Dr. Shailesh Shrikhande	Merck PVT Ltd.	Non-Govt.	Medical and Health Sciences	9/23/2013	8.90	9 Years	TMC
Protocol no. NOPRODPCR4001- A multicenter, prospective, longitudinal registry of patients with prostate cancer in Asia	Dr. Amit Joshi	Janssen Asia Pacific Medical Affairs	Non-Govt.	Medical and Health Sciences	9/21/2016	38.23	5 Years	TMC
Protocol No. RI-02-003- Reditux TM Registry to compare Effectiveness, Safety and Resource Utilization of Reditux vs. the Reference Medicinal Product to treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia in Routine Clinical Practice	Dr. Manju Sengar	DR.REDDYS LAB/Phamax Analytic Resources Pvt Ltd	Non-Govt.	Medical and Health Sciences	2/22/2016	32.64	6 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.


 प्रो. पी. डी. नाईक / Prof. P. D. Naik
 प्रिंसिपल, होमि भबहा नेशनल इंस्टीट्यूट
 प्रशिक्षण विद्यालय भवन, आनूशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Protocol Number: CO41101 A Phase III, Double Blind, Placebo Controlled, Randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel As a treatment for patients with Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer.	Dr. Sudeep Gupta	F. Hoffmann-La Roche Ltd	Non-Govt.	Medical and Health Sciences	9/21/2020	476.18	5 Years	TMC
Protocol Number: CO41101 A Phase III, Double Blind, Placebo Controlled, Randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel As a treatment for patients with Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer.	Dr. Sudeep Gupta	F. Hoffmann-La Roche Ltd	Non-Govt.	Medical and Health Sciences	9/21/2020	476.18	6 Years	TMC
Quality Assurance (QA) Program for Molecular Diagnostic testing in Solid Tumors	Dr. Omshree Shetty	NCG	Non-Govt.	Medical and Health Sciences	12/8/2017	111.06	5 Years	TMC
Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer	Dr. Nita Nair	DAE Capital budget	Govt.	Medical and Health Sciences	5/25/2010	79.89	15 Years	TMC
RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA	Dr. Reena Engineer	Extramural RTOG	Non-Govt.	Medical and Health Sciences	8/8/2020	275.22	5 Years	TMC
Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in hepatocellular carcinoma (IAEA study)	Dr. Supriya Chopra	IAEA	Non-Govt.	Medical and Health Sciences	11/22/2016	9.40	6 Years	TMC
Rapid Palliation in Locally Advanced Cervical Cancer: A Phase III randomized trial (RAPPAL Study)	Dr. Supriya Chopra	TF	Govt.	Medical and Health Sciences	2/5/2019	71.52	5 Years	TMC
RECAPP, Neutrino Physics & Astrophysics	Prof. Pinaki Majumdar	DAE	Govt.	Physical Sciences	2020	6.16	3 Years	HRI

Compilation of data as received from Dean-Academic of the various Cis/OCC of HBNI.

(Signature)

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशांक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Protocol No. - ALK19/ENZ137-BEV1 : A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer.	Dr. Vikas Ostwal	Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai 400013, Maharashtra, Enzene Biosciences Limited, Plot Number	Non-Govt.	Medical and Health Sciences	3/12/2021	13.18	1 Years 4 Months	TMC
Protocol No. - CBYL719C2301 : A phase III randomized double-blind, placebo controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment	Dr. Sudeep Gupta	Novartis Healthcare Private Limited	Non-Govt.	Medical and Health Sciences	7/21/2016	94.95	5 Years	TMC
Protocol No. - D3614C00001 : A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC).	Dr. Sudeep Gupta	Astra Zeneca Non-Govt. India Limited	Non-Govt.	Medical and Health Sciences	10/12/2020	545.53	2 Years 4 Months	TMC
Protocol No. - D3614C00001 : A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC).	Dr. Sudeep Gupta	AstraZeneca Non-Govt. India Limited	Non-Govt.	Medical and Health Sciences	10/12/2020	545.53	2 Years 4 Months	TMC
Protocol No. - D5161C00005 : A prospective, multicenter, Phase-IV clinical trial to assess safety of TAGRISSOTM (Osimertinib) in Indian adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive nonsmall cell lung cancer (NSCLC).	Dr. Vanita Noronha	AstraZeneca Non-Govt. India Limited	Non-Govt.	Medical and Health Sciences	1/21/2019	12.49	2 Years	TMC
Protocol No. - D9100C00001 : A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)	Dr. Sudeep Gupta	AstraZeneca Non-Govt. India limited.	Non-Govt.	Medical and Health Sciences	2/25/2020	389.15	4 Years	TMC
Protocol No. - D933AC00001 : A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)	Dr. Vikas Ostwal	Astra Zeneca Non-Govt. India Ltd.	Non-Govt.	Medical and Health Sciences	10/5/2020	118.59	2 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.

094
 प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डॉ. होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुसक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Protocol No. - D933AC00001 : A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durlavalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)	Dr. Vikas Ostwal	AstraZeneca Non-Govt. India Ltd.	Non-Govt.	Medical and Health Sciences	10/5/2020	118.59	2 Years	TMC
Protocol No. - DRL-INDG02-PAN/2018 : An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize its Safety, Tolerability and Activity in Indian Subjects with Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer	Dr. Vikas Ostwal	Dr. Reddy's Laboratories Ltd.	Non-Govt.	Medical and Health Sciences	5/13/2020	25.89	2 Years	TMC
Protocol No. - E7080-M091-507 : Prospective Single Arm Post Marketing Phase IV study to assess the Safety and Efficacy of Lenvatinib in Subjects with Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer	Dr. Vijay Patil	Eisai Non-Govt. ceuticals India Pvt. Ltd.	Non-Govt.	Medical and Health Sciences	10/31/2019	30.19	3 Years 1 Months	TMC
Protocol No. - ECTS/16/002 : A multicentric open label phase II safety and efficacy study of ormeloxifene in tamoxifen resistant metastatic/recurrent breast cancer patients.	Dr. Sudeep Gupta	HLL Lifecare Limited (A Government of India Enterprises)	Non-Govt.	Medical and Health Sciences	10/8/2018	48.70	4 Years	TMC
Protocol No. - EGC002 : A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer	Dr. Sudeep Gupta	Eirgenix Inc.	Non-Govt.	Medical and Health Sciences	7/1/2019	264.00	4 Years	TMC
Protocol No. - EIL-E7389-CT01-012 : Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Erlubin Mesylate in Treating Patients with Locally Advanced or Metastatic Breast Cancer.	Dr. Sudeep Gupta	Eisai Non-Govt. ceuticals India Private Limited	Non-Govt.	Medical and Health Sciences	8/16/2018	111.54	3 Years	TMC
Protocol No. - I3Y-CR-JPBQ : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSA1 plus Abemaciclib, a CDK4 and CDK6 inhibitor, or plus Placebo and to Compare Fulvestrant plus Abemaciclib or plus Placebo in Postmenopausal Women with Hormone Receptor-Positive,	Dr. Jyoti Bajpai	Eli Lilly and Company India Pvt. Ltd	Non-Govt.	Medical and Health Sciences	11/30/2016	116.30	6 Years	TMC
Protocol No. - LUF-44-001 Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Suyash Kulkarni	Guerbet	Non-Govt.	Medical and Health Sciences	2/27/2020	1.81	1 Years	TMC
Protocol No. - NEO - ALTO - CLAP016B2302 : A randomized, multicenter, open-label, phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.	Dr. Sudeep Gupta	GlaxoSmithKline Non-Govt. ceuticals Limited	Non-Govt.	Medical and Health Sciences	5/18/2009	27.02	13 Years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अनुशाक्तीनगर, मुंबई - 400
 Training School Complex, Anushaktinagar, Mumbai

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Precision medicine and Mainutrition- A Model based approach to dose chemotherapy in pediatric patients with mainutrition	Dr. Girish Chinnaswamy	Terry Fox Foundation	Non-Govt.	Medical and Health Sciences	5/8/2018	172.91	5 Years	TMC
Pregnancy Associated Cancer (PAC) Registry to collate data on epidemiology and treatment patterns & outcomes.*	Dr. Jyoti Bajpai	Roche Pvt. Ltd	Non-Govt.	Medical and Health Sciences	1/2/2017	13.88	6 Years	TMC
Prevalence and predictors of mainutrition and its impact on quality of life and prognosis in patients with hepato-biliary tumors - a prospective study	Dr. Prachi Patil	DAE	Govt.	Medical and Health Sciences	4/4/2018	10.17	4 Years	TMC
Prevalence of MMR status in gallbladder cancer (GBC) treated with palliative intent and its correlation with response to chemotherapy and survival.	Dr. Vikas Ostwal	Educational grant from Cadila healthcare limited	Non-Govt.	Medical and Health Sciences	5/27/2018	15.28	4 Years	TMC
Prevalence of RAS and BRAF mutations in subjects diagnosed with Colorectal Cancer- a prospective, single center study	Dr. Prachi Patil	Merck Inc. unrestricted educational grant.	Non-Govt.	Medical and Health Sciences	8/2/2013	12.50	7 Years 5 Months	TMC
Primary screening of high risk HPV DNA by a low cost molecular HPV test for early detection of cervical precancers and cancers among women in urban and rural community of Maharashtra	Dr. Sharmila Pimple	Department of Health Research (DHR)	Govt.	Medical and Health Sciences	11/13/2019	92.54	3 Years	TMC
Probing Heat Transport phenomena at Nanoscale using Raman Thermometry	Dr. Satyaprakash Sahoo	Science and Engineering Research Board	Govt.	Physical Sciences	2020-21	7.92	3 Years	(From IOP)
Probing Heat Transport phenomena at Nanoscale using Raman_x000D_ Thermometry	Dr. Satyaprakash Sahoo	Science and Engineering Research Board	Govt.	Physical Sciences	2020-21	7.92	3 years	IOP
Processing of waste placental tissue from maternity wards into regenerative tissue grafts for non-healing wounds and other clinical applications	Dr. Ajay Puri	DST	Govt.	Medical and Health Sciences	2021	50	2 years	TMC

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBNI

Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Govt./Non-Govt.)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project	Cis/OCC
Profiling the incidence of ROS1 alteration discovered in human Non Small Cell Lung Cancer	Dr. Kumar Prabhash	PFIZER, PVT LTD	Non-Govt.	Medical and Health Sciences	6/19/2017	42.59	3 Years	TMC
Prospective cohort study to determine the association of pre-operative nutritional status with 90 days morbidity among patients undergoing Radical cystectomy or Radical Cysto-Prostatectomy for Bladder Cancer	Dr. Ganesh Bakshi	DAE	Govt.	Medical and Health Sciences	10/24/2019	.11	2 Years 6 Months	TMC
Prospective observational cohort study of advanced Gall bladder cancer patients to study the impact of clinical and molecular characteristics and outcome	Dr. Vikas Ostwal	MERCK PVT LTD	Non-Govt.	Medical and Health Sciences	12/21/2015	39.66	7 Years	TMC
Prospective PeriOperative study Evaluating Routine Coagulation versus Thromboelastography for Liver resections (More Than Three Segments) (PORTAL Trial)	Dr. Reshma Ambulkar	TRAC	Non-Govt.	Medical and Health Sciences	2/27/2020	1.23	1 Years	TMC
Prospective study to identify biomarkers of chemoresistance to neoadjuvant chemotherapy and discover targetable pathways in triple-negative breast cancer.	Dr. Nita Nair	TF / DBT / DST	Govt.	Medical and Health Sciences	4/12/2018	42.85	4 Years	TMC
Protocol No. - 0063-17 : A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.	Dr. Sudeep Gupta	Intas ceuticals Ltd., Corporate Office Bldg , Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India	Non-Govt.	Medical and Health Sciences	9/27/2018	244.65	4 Years	TMC
Protocol No. - ALK18/ENZ124-CET1 : A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).	Dr. Kumar Prabhash	ALKEM LABORATORIES LIMITED	Non-Govt.	Medical and Health Sciences	10/18/2019	146.84	2 Years 10 Months	TMC
Protocol No. - ALK19/ENZ137-BEV1 : A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer.	Dr. Vikas Ostwal	Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai 400013, Maharashtra, Enzene Biosciences Limited, Plot Number	Non-Govt.	Medical and Health Sciences	3/12/2021	13.18	1 Years 4 Months	TMC

Compilation of data as received from Dean-Academic of the various Cis/Occ of H3NP

डॉ. पी. टी. नाईक / प्रो. पी. टी. नाईक

डीन, होमो ओपेन नॅशनल इंस्टीट्यूट

Dean, Homi Bhabha National Institute

प्रशिक्षण विद्यालय भवन, अणुशक्तिनगर, मुंबई - 400 094

Training School Complex, Anushaktinagar, Mumbai - 41